We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

By LabMedica International staff writers
Posted on 10 Jan 2025
Print article
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company Innovaccer Inc. (San Francisco, CA, USA) with the aim of improving patient outcomes and experience through novel digital and diagnostic solutions. The investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Innovaccer has developed a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, aims to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

"Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

"Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time," said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. "We're excited to connect our innovation ecosystem with Innovaccer's to enable this healthcare transformation."

"At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of Innovaccer. "We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions."

Related Links:
Danaher Corporation
Innovaccer Inc.

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Malaria Rapid Test
ASSURE Malaria P.f/P.v Rapid Test
New
Carcinoembryonic Antigen Test
CEA Test

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.